Visalytics
Visalytics
approved EB-2 (NIW) RFE Issued

Process Chemist

Organic Chemistry · China · 2025-11-26

Processing Time
364 days
Decision Date
2025-11-26
Location
Pennsylvania
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop practical and efficient synthetic routes to produce active pharmaceutical ingredients (APIs) for drugs currently in clinical trials. This work focuses on improving scalable production methods to reduce costs and shorten development timelines for new therapies targeting cancer and neurodegenerative disorders.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The work addresses national challenges in healthcare by accelerating the delivery of effective therapies for diseases like Alzheimer's.

2 Well-positioned to Advance the Endeavor Met

The petitioner's 8 publications and 300+ citations demonstrate significant influence in the field of organic synthesis.

3 Balance of Factors Met

The U.S. benefits from waiving the labor certification to ensure continued innovation in drug discovery and manufacturing.

Why This Petition Was Approved

The petition was approved based on the petitioner's Ph.D. in Chemistry and a record of 8 peer-reviewed journal articles with over 300 citations. These metrics, combined with evidence of the work's application in drug development for serious diseases, satisfied all three Dhanasar prongs.

Request for Evidence (RFE)

Successfully Addressed

The RFE requested further evidence regarding the national importance of the work and the petitioner's positioning. The response provided focused materials that clarified the endeavor's value to public health and strengthened the proof of the petitioner's research influence.

RFE Targets
Substantial Merit and National ImportanceWell-positioned to Advance the Endeavor

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Original Contributions

Similar Cases

Scientist

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved
Massachusetts 69 days 2022-04-19
The petitioner proposes to continue analyzing synthetic routes to isolate, synthesize, design, and ensure the safety of novel drug molecules. This work is part of innovative drug discovery projects aimed at treating cancer, heart disease, and infectious diseases to improve global and U.S. healthcare outcomes.
View Case

Scientist

Pharmaceuticals · New Zealand

WeGreened EB-2 (NIW) approved
California 467 days 2025-03-05
The petitioner proposes to design and optimize novel small-molecule therapeutics to improve cancer patient outcomes, specifically targeting difficult-to-treat cancers. Their work involves leveraging synthetic organic chemistry and catalysis to develop innovative approaches for constructing biologically active lead compounds with enhanced pharmacological profiles.
View Case

Research Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
Indiana 25 days 2023-10-20
The petitioner proposes to continue developing small-molecule ligands and chemical constituents for use in drug discovery and pharmaceutical development. This work focuses on the creation of anti-diabetic and anti-cancer compounds, as well as the design of FAP-targeted ligands with therapeutic applications. The research aims to advance pharmaceutical innovation and improve human health outcomes through more efficient drug synthesis methodologies.
View Case

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
Wisconsin 94 days 2025-01-29
The petitioner proposes to investigate the design, synthesis, optimization, and characterization of small molecule compounds. This work focuses on developing therapeutic agents to address drug-resistant infections and improve medication safety and efficacy.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from China

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-11-26.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 364 days
RFE Issued
Criteria Met 3 / 3
Evidence Types 3

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,814
Success Rate 53.6%
Sustained 2,046
Dismissed 1,672

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in China All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist